Project description
New pharmacological treatment for Down’s syndrome
Down’s syndrome (DS) is caused by an extra copy of all or part of the long arm of human chromosome 21. DS causes lifelong cognitive impairments (CIs) which have a significant negative impact on the individuals, their families and society. However, there are currently no approved pharmacological treatments for CIs in people with DS. The EU-funded ICOD project aims to fill this gap by providing a feasibility demonstration of a new therapy for CIs in DS. It will perform first-in-humans and efficacy clinical trials with a new molecular entity (AEF0217), which reverses CIs in animal models of DS. AEF0217 belongs to a new pharmacological class developed by the biotech Aelis Farma: the Signaling Specific Inhibitors of the Cannabinoid (CB1) receptor (CB1-SSi). ICOD will enable a safe and efficacious pharmacological treatment of CIs in people with DS.
Fields of science
Programme(s)
Call for proposal
H2020-SC1-2020-Two-Stage-RTD
See other projects for this call
Funding Scheme
RIA - Research and Innovation actionCoordinator
08003 Barcelona
Spain
Participants (5)
33077 Bordeaux
94018 Troina
75725 Paris
42055 Saint Etienne
28020 Madrid